Large Japanese Pharmas Seek To Fill Domestic Gap For Obesity Drugs
This article was originally published in PharmAsia News
Several of the larger Japanese drug makers are focusing on developing drugs aimed at treating obesity in a segment of the domestic population for which few medicines exist. Eisai has applied for approval of a drug by U.S.-based Abbott Laboratories that causes brain neurotransmitters to fool the body to believe it is full. Shionogi and Takeda Pharmaceutical also have anti-obesity drugs in their pipelines, Shionogi is set to begin human clinical trials this summer and Takeda is watching Phase III trials for a drug it licensed from a U.K. bioventure. (Click here for more - a subscription may be required
You may also be interested in...
The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.
Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.